Takayasu Arteritis Management and Prognosis

Clinical Presentation and Diagnosis

The Indian type of Takayasu arteritis primarily affects the abdominal aorta and renal arteries, according to the American Heart Association 1
Diminished or absent peripheral pulses are a common physical examination finding in patients with Takayasu arteritis, as noted by the American College of Cardiology 1
Blood pressure discrepancy >10 mmHg between arms is a significant finding in Takayasu arteritis, as reported by the American Heart Association 1
Vascular bruits over subclavian arteries or aorta are a characteristic physical examination finding in patients with Takayasu arteritis, according to the American College of Cardiology 1
Aortic coarctation is a differential diagnosis for Takayasu arteritis, as noted by the American Heart Association 1

Diagnostic Approach

Angiographic evidence of aorta or branch vessel stenosis is a key criterion for diagnosing Takayasu arteritis, according to the American College of Rheumatology 1
Imaging with thoracic aorta and branch vessel CT or MRI is essential for detecting aneurysms or occlusive disease in patients with Takayasu arteritis, as recommended by the American Heart Association 1

Differential Diagnosis

Giant cell arteritis is a differential diagnosis for Takayasu arteritis, typically affecting older patients, as noted by the European League Against Rheumatism 2
Fibromuscular dysplasia is a differential diagnosis for Takayasu arteritis, as reported by the European League Against Rheumatism 2
Other large vessel vasculitides are differential diagnoses for Takayasu arteritis, according to the European League Against Rheumatism 2

Management

High-dose oral prednisone (40-60 mg daily) is the initial corticosteroid therapy for Takayasu arteritis, as recommended by the European League Against Rheumatism 2 and the American Heart Association 1
Methotrexate (20-25 mg/week) or azathioprine (2 mg/kg/day) can be used as steroid-sparing agents in the treatment of Takayasu arteritis, according to the European League Against Rheumatism 2
TNF inhibitors can be considered for refractory cases of Takayasu arteritis, as noted by the European League Against Rheumatism 2
Low-dose aspirin may be beneficial to prevent ischemic events in patients with Takayasu arteritis, as recommended by the European League Against Rheumatism 2

Surgical/Interventional Management

Elective revascularization should be delayed until the acute inflammatory state is treated and quiescent, as recommended by the European League Against Rheumatism 2 and the American Heart Association 1
Endovascular options, such as balloon angioplasty or stent placement, can be used for critical stenosis or aneurysm formation, according to the European League Against Rheumatism 2
Surgical bypass grafting is a treatment option for long-segment stenosis, as noted by the European League Against Rheumatism 2

Monitoring

Regular clinical assessment and measurement of inflammatory markers (ESR/CRP) are essential for monitoring disease activity in patients with Takayasu arteritis, as recommended by the European League Against Rheumatism 2
Periodic imaging with MRI or CT is necessary to assess disease activity and detect complications, according to the European League Against Rheumatism 2

Takayasu Arteritis Characteristics and Manifestations

Pathophysiology and Vascular Involvement

Takayasu arteritis is defined as an idiopathic vasculitis of elastic arteries, with the primary pathological process affecting the aorta and its major branches 3
The disease is characterized as a T-cell-mediated panarteritis that proceeds from adventitial vasa vasorum involvement inward 4
The inflammatory process leads to two primary outcomes: destruction yielding aneurysms or fibrosis causing stenosis of affected arteries 4
The 1990 American College of Rheumatology diagnostic criteria specifically focus on arterial involvement, with no mention of venous pathology 4

Clinical Manifestations

The clinical manifestations of Takayasu arteritis typically develop in two phases, including an acute phase with constitutional symptoms and a chronic phase with symptoms related to arterial involvement 5
Common complications include arterial stenosis (occurring in 53% of patients in the NIH series) 5
Aneurysm formation occurs in 23-32% of patients 5
Hypertension due to renal artery involvement is a complication of Takayasu arteritis 3

Diagnostic Imaging and Treatment

Guidelines recommend thoracic aorta and branch vessel computed tomographic imaging or magnetic resonance imaging to investigate aneurysm or occlusive disease in arteries 6
The American College of Rheumatology recommends treatment of Takayasu arteritis with high-dose corticosteroids (prednisone 40-60 mg daily) 6
Second-line agents include methotrexate, azathioprine, and anti-TNF-alpha agents, as recommended by the American College of Rheumatology 5

Comparison with Other Vasculitides

Unlike Takayasu arteritis, Behçet disease is one of only two vasculitides that commonly involves veins, causing venous thrombophlebitis, deep vein thrombosis, vena cava thrombosis, and cerebral sinus thrombosis 7
The American College of Rheumatology notes that this distinction between Takayasu arteritis (arterial involvement) and Behçet disease (arterial and venous involvement) is important for differential diagnosis 7

Diagnostic Testing and Treatment for Takayasu Arteritis

Diagnostic Approach

When Takayasu arteritis is suspected, perform a thorough clinical examination of the arterial tree combined with imaging assessment using MRI/CT angiography or conventional angiography to document the extent and pattern of arterial involvement, as recommended by the American College of Rheumatology 8
Imaging is essential since there is no gold standard diagnostic test or specific autoantibody for Takayasu arteritis, according to the American College of Rheumatology 9

Imaging Studies

Conventional angiography should be considered when MRI/CT are unavailable, as it remains the gold standard for evaluating vascular lesions, as stated by the American College of Cardiology 9
PET imaging, such as FDG-PET, can assist in documenting arterial involvement and assessing disease activity, though it requires formal validation, as recommended by the American College of Radiology 9

Management

Takayasu arteritis should be managed at an expert center due to the rarity of the disease, limited availability of specialist imaging and vascular surgery, and the complexity of treatment, as recommended by the American College of Rheumatology 8, 9

Differentiating Aortitis Conditions

Age and Demographics

The American College of Rheumatology suggests that Takayasu arteritis predominantly affects younger women, typically under 40 years of age, which is a critical distinguishing feature from other forms of aortitis 10, 11

Clinical Presentation Patterns

The American College of Rheumatology recommends considering Takayasu arteritis in patients presenting with constitutional symptoms followed by vascular manifestations (biphasic presentation) 10, 11
Arterial stenosis and aneurysms affecting the aorta and major branches are key imaging findings in Takayasu arteritis, according to the American College of Rheumatology 10, 11

Imaging Characteristics

The American College of Rheumatology states that angiographic patterns in Takayasu arteritis show six distinct clusters with characteristic involvement of the aorta and its major branches, including arterial stenosis and aneurysms affecting the aorta and major branches 10, 11

Investigation and Management of Takayasu Arteritis

Initial Diagnostic Workup

The American College of Rheumatology recommends using noninvasive vascular imaging (CT angiography, MR angiography, or FDG-PET) combined with clinical assessment and inflammatory markers for diagnosis and monitoring of Takayasu arteritis, with regularly scheduled imaging every 3-6 months during active disease 12, 13, 14
Inflammatory markers (ESR/CRP) should be measured, though they are elevated in only 50% of cases and are imperfect indicators of disease activity 14

Imaging Strategy

Noninvasive imaging, such as CT angiography (most commonly used for diagnosis at 58.8%), MR angiography (preferred for follow-up at 62.3%), or FDG-PET, should be performed as first-line, as they provide information about vascular wall inflammation, not just luminal changes 12, 13
Catheter angiography should be reserved for determining central blood pressures, surgical planning, or when noninvasive modalities are inadequate 13

Ongoing Monitoring Protocol

Long-term clinical monitoring is strongly recommended even in apparent remission, given minimal risks and potential catastrophic outcomes without monitoring 12, 14
Regular noninvasive imaging should be scheduled in addition to clinical assessment, as vascular changes can occur when disease appears clinically quiescent 13, 14
Imaging intervals should be every 3-6 months during early/active disease, with longer intervals for established quiescent disease 13

Management Decisions Based on Findings

New arterial stenosis or vessel wall thickening in new territories on imaging warrants immunosuppressive therapy, even if clinically asymptomatic 13, 15
Active disease findings include vascular edema, contrast enhancement, increased wall thickness on MR/CT angiography, or supraphysiologic FDG uptake on PET 15
Surgical intervention should be delayed until disease is quiescent whenever possible, as observational studies show improved outcomes 15

Common Pitfalls to Avoid

Inflammatory markers should not be relied upon solely for disease activity assessment, as they can be nonspecific and normal in active disease 12, 14
Catheter angiography should not be used as routine monitoring, as it only shows luminal changes and misses wall inflammation 12, 13
Surgery should not be performed during active inflammation unless life- or organ-threatening, as outcomes are worse 15

Management of Takayasu Arteritis

Initial Medical Management

The American College of Rheumatology recommends initiating treatment with high-dose oral glucocorticoids (prednisone 1 mg/kg/day or 40-60 mg daily) combined with a non-glucocorticoid immunosuppressive agent, preferably methotrexate (20-25 mg/week), for patients with active Takayasu arteritis 16, 17, 18, 19
For newly diagnosed active TAK, start high-dose oral glucocorticoids (prednisone 1 mg/kg/day, up to 80 mg) immediately and simultaneously add a non-glucocorticoid immunosuppressive agent to minimize glucocorticoid toxicity 16, 17, 18, 19, 20, 21
IV pulse methylprednisolone (500-1,000 mg/day for 3-5 days) is not superior to high-dose oral glucocorticoids and should be reserved only for life- or organ-threatening disease (vision loss, stroke, cardiac ischemia, limb ischemia) 18

Refractory Disease Management

For patients failing initial therapy with glucocorticoids and conventional immunosuppressants, TNF inhibitors are conditionally recommended over tocilizumab as the next step 18
Tocilizumab should be reserved for cases where TNF inhibitors are contraindicated, ineffective, or not tolerated 18

Glucocorticoid Tapering Strategy

For patients achieving remission on glucocorticoids for ≥6-12 months, taper off glucocorticoids completely rather than maintaining long-term low-dose therapy 18
Continue non-glucocorticoid immunosuppressive agents during and after taper 18

Monitoring and Disease Activity Assessment

The American College of Rheumatology strongly recommends long-term clinical monitoring for all TAK patients, including those in apparent remission 17, 19, 22, 20, 21
Assess for clinical signs/symptoms of active disease at each visit 16
Obtain four-extremity blood pressures at every assessment 16
Measure inflammatory markers (ESR, CRP) alongside clinical assessment 17, 19, 22, 20, 21

Surgical and Interventional Management

For patients requiring vascular surgery (bypass, angioplasty, stent placement), delay surgical intervention until disease is quiescent whenever possible, unless life- or organ-threatening ischemia is present 22, 21
Use high-dose glucocorticoids in the periprocedural period 22, 20, 21

Special Populations

Methotrexate is preferred in children due to better tolerability 17, 19, 20
Alternate steroid dosing regimens (IV pulse with low daily oral dosing) may improve compliance and reduce growth impairment in children 18

Key Clinical Pitfalls to Avoid

Do not rely on inflammatory markers alone for disease activity assessment—they are normal in 50% of active cases 17, 19, 22, 20, 21
Do not use glucocorticoid monotherapy except for mild disease or uncertain diagnosis—combination therapy reduces glucocorticoid toxicity 16, 17, 18, 19, 20, 21
Do not perform elective surgery during active inflammation—outcomes are significantly worse 22, 21
Do not discontinue monitoring in clinical remission—vascular changes occur when disease appears quiescent 17, 19, 22, 20, 21

Treatment Approach for Renal Artery Stenosis in Takayasu Arteritis

Initial Management Strategy

For patients with Takayasu arteritis and renovascular hypertension from renal artery stenosis, the American College of Rheumatology recommends medical management with antihypertensive drugs and immunosuppressive therapy as the preferred initial approach, reserving surgical or catheter-based interventions for hypertension refractory to optimized medical therapy or worsening renal function 23
Medical management addresses both the inflammatory process and its hemodynamic consequences, with the goal of controlling vascular inflammation to improve or prevent worsening blood flow without the risks of intervention 24

Interventional Therapy

Surgical or catheter-based intervention becomes appropriate when hypertension remains refractory despite optimized medical management and optimized immunosuppressive therapy, or when progressive worsening of renal function occurs despite medical therapy, according to the American College of Rheumatology 23, 24
The American College of Rheumatology also recommends that elective revascularization must be delayed until the acute inflammatory state is treated and quiescent, as performing surgery during active disease yields worse outcomes unless life- or organ-threatening manifestations are present 23, 24

Collaborative Decision-Making

The American College of Rheumatology suggests that any patient requiring surgical vascular intervention requires collaborative decision-making between the vascular surgeon and rheumatologist to ensure accurate assessment of disease activity before intervention, optimal timing of procedures, and appropriate perioperative immunosuppression 23, 24

Perioperative Management

If surgical intervention proceeds with active disease present, the American College of Rheumatology recommends using high-dose glucocorticoids in the periprocedural period, specifically for vascular surgical interventions performed due to complications of Takayasu arteritis 23, 24

Management of Takayasu Arteritis During Pregnancy

Monitoring and Disease Management

Vascular examination for new bruits or pulse deficits should be performed at each prenatal visit, as recommended by the American Heart Association, to detect new stenoses 25
If new disease activity develops during pregnancy, initiate or increase corticosteroids immediately, with prednisone 40-60 mg daily for active inflammation, as suggested by the American College of Cardiology 25
Delay any elective revascularization procedures until after delivery and disease quiescence, unless life- or organ-threatening ischemia is present, as recommended by the American Heart Association 25

Diagnostic Approach and Management of Large Vessel Vasculitis (Takayasu Arteritis)

Clinical Recognition and Initial Assessment

The European League Against Rheumatism (EULAR) recommends immediate initiation of high-dose oral glucocorticoids (40-60 mg/day prednisone) when clinical suspicion of Takayasu arteritis is high, even before imaging confirmation, to prevent irreversible ischemic complications 26, 27, 28
Constitutional symptoms such as weight loss, low-grade fever, fatigue, and night sweats, as well as vascular manifestations like hypertension, new loss of pulses, and vascular bruits, should raise suspicion for Takayasu arteritis 26, 27
Life-threatening presentations, including stroke, seizures, syncope, and myocardial infarction, require urgent evaluation and treatment 26, 27

Imaging Strategy

PET-CT (FDG-PET) can assist in documenting arterial involvement and assessing disease activity, showing supraphysiologic FDG uptake in active disease 29
Ultrasound has limited evidence for carotid and subclavian ultrasonography in Takayasu arteritis monitoring, and is less commonly used than in giant cell arteritis 30

Diagnostic Confirmation and Referral

A suspected diagnosis must be confirmed by imaging demonstrating aortic or branch vessel stenosis, occlusion, or aneurysm, and patients should be referred to an experienced center for multidisciplinary diagnostic workup and management 26, 31

Monitoring Protocol After Diagnosis

All patients require lifelong monitoring given the catastrophic potential outcomes, and imaging intervals should be extended but maintained long-term in established quiescent disease 30
Clinical monitoring at each visit should include four-extremity blood pressures, vascular examination, assessment for clinical signs/symptoms of active disease, and inflammatory markers (ESR, CRP) alongside clinical assessment 30

Treatment of Takayasu Arteritis

Initial Medical Management

The American College of Rheumatology recommends initiating high-dose oral glucocorticoids (40-60 mg daily or 1 mg/kg/day) combined with a non-glucocorticoid immunosuppressive agent, such as methotrexate (20-25 mg/week), for patients with active Takayasu arteritis 32, 33
The American College of Rheumatology/Vasculitis Foundation guidelines explicitly recommend against glucocorticoid monotherapy for most patients, as combination therapy significantly reduces glucocorticoid toxicity and improves long-term outcomes 32, 33

Refractory Disease Management

For patients failing glucocorticoids plus conventional immunosuppressants, the American College of Rheumatology recommends adding a TNF inhibitor rather than tocilizumab as the next therapeutic step 32, 33
The American College of Rheumatology prioritizes TNF inhibitors for refractory disease based on broader evidence, despite a study showing tocilizumab achieved faster remission than cyclophosphamide 32, 33

Surgical and Interventional Management

The American College of Rheumatology recommends delaying elective revascularization until disease is quiescent, as performing surgery during active inflammation yields significantly worse outcomes 32, 33
For patients with active disease, the American College of Rheumatology recommends using high-dose glucocorticoids in the periprocedural period and ensuring collaborative decision-making between vascular surgeon and rheumatologist for all surgical interventions 32, 33

Glucocorticoid Tapering Strategy

After achieving remission on glucocorticoids for 6-12 months, the American College of Rheumatology recommends tapering off glucocorticoids completely rather than maintaining long-term low-dose therapy 32, 33

Adjunctive Antiplatelet Therapy

The American College of Rheumatology recommends adding aspirin or another antiplatelet agent for patients with active disease and critical cranial or vertebrobasilar involvement 32, 33

Monitoring Protocol

The American College of Rheumatology recommends measuring inflammatory markers (ESR, CRP) alongside clinical assessment, but notes that inflammatory markers are elevated in only 50% of active cases and should never be relied upon solely for disease activity assessment 32, 33

Management of Takayasu Arteritis

Initial Medical Therapy

The American College of Rheumatology recommends initiating high-dose oral glucocorticoids (prednisone 40-60 mg daily or 1 mg/kg/day) combined with a non-glucocorticoid immunosuppressive agent for patients with active Takayasu arteritis, with glucocorticoid monotherapy avoided except in mild or uncertain cases 34, 35
Methotrexate (20-25 mg/week) is the preferred first-line steroid-sparing agent, particularly in children due to superior tolerability, with alternative first-line agents including azathioprine (2 mg/kg/day) or TNF inhibitors 34, 35

Management of Refractory Disease

For patients failing initial therapy with glucocorticoids plus conventional immunosuppressants, the American College of Rheumatology recommends adding a TNF inhibitor rather than tocilizumab as the next therapeutic step 34, 35
TNF inhibitors have more extensive clinical experience and observational data demonstrating induction of remission and decreased relapses in Takayasu arteritis, with tocilizumab reserved for cases where TNF inhibitors are contraindicated, ineffective, or not tolerated 35

Glucocorticoid Tapering Strategy

After achieving remission on glucocorticoids for 6-12 months, the American College of Rheumatology recommends tapering off glucocorticoids completely rather than maintaining long-term low-dose therapy, with continued non-glucocorticoid immunosuppressive agents during and after the glucocorticoid taper 34, 35

Disease Activity Monitoring

The American College of Rheumatology recommends lifelong clinical monitoring for all patients with Takayasu arteritis, even those in apparent remission, with measurement of inflammatory markers (ESR, CRP) alongside clinical assessment 34, 35
Noninvasive imaging (MRI/CT angiography or FDG-PET) is preferred over catheter-based angiography for disease activity assessment, with regular noninvasive imaging every 3-6 months during active/early disease 34

Surgical and Interventional Management

The American College of Rheumatology recommends delaying elective revascularization until disease is quiescent whenever possible, with surgery during active inflammation yielding significantly worse outcomes 34, 35
High-dose glucocorticoids should be used in the periprocedural period if the patient has active disease, with collaborative decision-making between vascular surgeon and rheumatologist for all surgical interventions 34, 35

Special Populations: Pediatric Patients

Methotrexate is the preferred first-line steroid-sparing agent in children due to better tolerability, with consideration of cyclophosphamide induction followed by methotrexate maintenance for children with widespread disease involving both sides of the diaphragm 34, 35

Management of Takayasu Arteritis – Evidence‑Based Recommendations

First‑Line Therapy

Initiate high‑dose oral glucocorticoids (prednisone 40–60 mg daily or ≈1 mg/kg/day, max 80 mg) combined with a non‑glucocorticoid immunosuppressive agent at the time of diagnosis; glucocorticoid monotherapy is reserved only for mild disease or diagnostic uncertainty because combination therapy markedly reduces long‑term steroid toxicity and improves clinical outcomes. Strength: expert consensus/observational data. [36][37]38
Begin prednisone at the above dose as soon as clinical suspicion is high, even before confirmatory imaging, to achieve rapid disease control. Strength: expert consensus. 36
After achieving remission (typically 6–12 months), taper glucocorticoids completely while maintaining the non‑glucocorticoid immunosuppressive agent throughout and after the taper. Strength: expert consensus. 38

Steroid‑Sparing Immunosuppressants (First‑Line Options)

Methotrexate (≈20–25 mg weekly) is the preferred first‑line steroid‑sparing agent, especially in children, owing to superior tolerability. Strength: observational data. [39][38]
Azathioprine (≈2 mg/kg/day) is an acceptable alternative first‑line agent when methotrexate is unsuitable. Strength: observational data. [39][38]
TNF‑α inhibitors (infliximab or adalimumab) may be used as initial adjunctive therapy together with glucocorticoids in patients where rapid disease control is desired or when conventional agents are contraindicated. Strength: expert consensus/observational data. 38

Management of Refractory Disease

In patients who fail glucocorticoids plus conventional immunosuppressants (methotrexate or azathioprine), add a TNF‑α inhibitor rather than tocilizumab as the next therapeutic step; this recommendation is based on broader clinical experience and observational studies showing higher remission rates and fewer relapses with TNF blockade. Strength: observational data. 38
Tocilizumab should be reserved for cases where TNF‑α inhibitors are contraindicated, ineffective, or not tolerated. A single randomized trial failed to meet its primary efficacy endpoint, although subsequent observational studies suggest benefit in selected refractory patients. Strength: randomized trial (negative) + observational data. 38
Abatacept is not recommended; a small randomized controlled trial demonstrated lack of efficacy in Takayasu arteritis. Strength: randomized trial. 38

Disease Activity Monitoring & Imaging

Lifelong clinical surveillance is mandatory because vascular remodeling can progress even when patients appear clinically quiescent. Strength: expert consensus. 38
At every visit obtain four‑extremity blood pressures, perform a vascular examination for new bruits or pulse deficits, assess constitutional (fever, weight loss, fatigue) and vascular symptoms (claudication, hypertension), and measure inflammatory markers (ESR, CRP). Strength: expert consensus. [38][39]
Inflammatory markers are elevated in only ~50 % of active disease episodes; therefore, they must not be used in isolation to assess activity. Clinical assessment combined with imaging is essential. Strength: observational data. 39
Imaging (MRI/CT angiography or FDG‑PET) every 3–6 months is recommended during active or early disease, with longer intervals once disease is established as quiescent. Findings indicating active inflammation include vascular wall edema, contrast enhancement, increased wall thickness on MR/CT, and supraphysiologic FDG uptake on PET. Strength: expert consensus/observational data. 38

Surgical and Interventional Considerations

Elective revascularization procedures (bypass grafting, angioplasty, stenting) should be postponed until disease is quiescent; operating during active inflammation is associated with significantly worse outcomes. Strength: expert consensus/observational data. [39][38]
If surgery is unavoidable because of life‑ or organ‑threatening ischemia, high‑dose glucocorticoids should be administered in the peri‑procedural period, and decisions should be made jointly by vascular surgeons and rheumatologists. Strength: expert consensus. 38

Adjunctive Antiplatelet Therapy

Add aspirin (75–150 mg daily) or another antiplatelet agent for patients with active disease and critical cranial or vertebrobasilar involvement. Small observational studies suggest a reduced risk of ischemic events, although bleeding risk is increased and caution is required after surgical procedures or in patients with high bleeding propensity. Strength: observational data. [39][38]

Pediatric Considerations

In children, methotrexate remains the preferred first‑line steroid‑sparing agent because of better tolerability compared with other immunosuppressants. Strength: observational data. 38

All bullet points include at least one citation identifier and reflect the strength of evidence where reported.

Evidence‑Based Guidelines for Takayasu Arteritis (Cited Findings)

Epidemiology & Demographics

Takayasu arteritis is an idiopathic granulomatous vasculitis of the aorta and its major branches that predominantly affects women younger than 40 years, with a female‑to‑male ratio of approximately 10:1. 40

Clinical Presentation

The disease typically follows a biphasic course: an initial acute phase characterized by constitutional symptoms (fever, weight loss, fatigue, night sweats) followed by a chronic phase dominated by vascular manifestations such as hypertension, limb claudication, diminished or absent peripheral pulses, audible bruits over large vessels, and a systolic blood‑pressure difference greater than 10 mm Hg between the arms. 41
Vascular involvement patterns differ by geographic type: the “Japanese type” mainly involves the thoracic aorta and great vessels, whereas the “Indian type” preferentially affects the abdominal aorta and renal arteries, leading to more frequent lower‑extremity claudication and renovascular hypertension. 40

Physical Examination Findings

Audible bruits over the subclavian, carotid, or abdominal aorta are characteristic physical signs of Takayasu arteritis. 40
A systolic blood‑pressure discrepancy greater than 10 mm Hg between the two arms serves as a significant diagnostic clue. 40

Imaging Strategy

Initial diagnostic work‑up should include imaging of the thoracic aorta and its branch vessels using computed tomography angiography (CTA), magnetic resonance angiography (MRA), or ^18F‑FDG PET‑CT to detect aneurysmal or occlusive disease. 40
CTA is the most frequently employed modality for initial diagnosis, utilized in approximately 58.8 % of cases, owing to its high spatial resolution and rapid acquisition time. 41
MRA is preferred for longitudinal monitoring (used in about 62.3 % of follow‑up examinations) because it avoids ionizing radiation and provides superior assessment of vessel‑wall inflammation. 41
^18F‑FDG PET‑CT can demonstrate arterial involvement and assess disease activity by revealing supraphysiologic FDG uptake in inflamed vessel walls, although formal validation of this technique remains pending. 41

First‑Line Medical Management

At diagnosis, high‑dose oral glucocorticoids (prednisone 40–60 mg daily or 1 mg/kg/day) should be started in combination with a non‑glucocorticoid immunosuppressive agent; glucocorticoid monotherapy is reserved only for mild disease or when the diagnosis is uncertain. 40

Surgical & Interventional Management

Elective revascularization procedures (bypass grafting, angioplasty, stenting) must be postponed until the disease is clinically quiescent, because operating during active inflammation is associated with markedly poorer outcomes. 40

Evidence‑Based Management of Takayasu Arteritis

Initial Medical Therapy

Initiate high‑dose oral glucocorticoids (prednisone 40–60 mg daily or ≈1 mg/kg/day) combined with a non‑glucocorticoid immunosuppressive agent—preferably methotrexate 20–25 mg weekly—at the time of diagnosis for all patients with active disease. 42
Glucocorticoid monotherapy is not recommended except in cases of mild disease or diagnostic uncertainty, because combination therapy markedly reduces long‑term steroid toxicity and improves clinical outcomes. 42
Methotrexate is the preferred first‑line steroid‑sparing agent, especially in pediatric patients, due to superior tolerability compared with other conventional immunosuppressants. 42

Glucocorticoid Tapering Strategy

After achieving clinical remission for 6–12 months, glucocorticoids should be tapered completely rather than maintained at a low dose, while continuing the non‑glucocorticoid immunosuppressive agent throughout and after the taper. 42
The taper is permissible only while the patient remains in clinical remission; emergence of constitutional or vascular symptoms (e.g., fever, weight loss, claudication, new bruits, pulse deficits, neurological changes) requires slowing or reversing the taper. 42

Management of Refractory Disease

In patients who fail glucocorticoids plus conventional immunosuppressants (methotrexate or azathioprine), the next therapeutic step should be the addition of a TNF inhibitor (e.g., infliximab or adalimumab) rather than tocilizumab, based on observational data showing higher remission rates and fewer relapses with TNF blockade. 42
Tocilizumab is reserved for cases where TNF inhibitors are contraindicated, ineffective, or not tolerated. 42
Abatacept is not recommended, as a randomized controlled trial demonstrated lack of efficacy in Takayasu arteritis. 42

Disease Activity Monitoring

Lifelong clinical surveillance is mandatory for all patients, even those in apparent remission, because vascular remodeling can progress silently. 42
At each visit, obtain four‑extremity blood pressures, perform a vascular examination for new bruits or pulse deficits, assess constitutional and vascular symptoms, and measure inflammatory markers (ESR, CRP) in conjunction with clinical assessment. 42
Inflammatory markers are elevated in only ≈50 % of active disease episodes; therefore, they must never be used in isolation to assess activity. 42

Imaging Protocol

Schedule non‑invasive imaging (MRI/CT angiography or FDG‑PET) every 3–6 months during active or early disease, extending the interval once disease is established as quiescent. 42
MRI/CT angiography is preferred for longitudinal monitoring (used in the majority of follow‑up examinations) because it avoids ionizing radiation and provides superior assessment of vessel‑wall inflammation. 42
Catheter angiography should be avoided for routine monitoring; it visualizes only luminal changes and misses wall inflammation, and is reserved for central pressure measurement or surgical planning. 42

Surgical and Interventional Timing

Elective revascularization procedures (bypass grafting, angioplasty, stenting) should be delayed until disease is quiescent, as operating during active inflammation is associated with significantly worse outcomes. 42
Urgent surgery is permitted only for life‑ or organ‑threatening ischemia (e.g., impending stroke, progressive tissue infarction, high‑risk aortic aneurysm). 42
If surgery must be performed during active disease, administer high‑dose glucocorticoids in the peri‑procedural period. 42
All surgical decisions require collaborative planning between a vascular surgeon and a rheumatologist to ensure accurate assessment of disease activity, optimal timing, and appropriate peri‑operative immunosuppression. 42

Adjunctive Antiplatelet Therapy

Add aspirin (75–150 mg daily) or another antiplatelet agent for patients with active disease and critical cranial or vertebrobasilar involvement. 42
Small observational studies suggest a reduced risk of ischemic events with antiplatelet use, although bleeding risk is increased; caution is advised after surgical procedures or in patients with high bleeding propensity. 42

Duration of Immunosuppression After Steroid Discontinuation

Continue non‑glucocorticoid immunosuppressive agents (methotrexate, azathioprine, or biologics) for at least 12–24 months after successful steroid discontinuation in sustained remission. 42
Taper immunosuppressive therapy only under close monitoring with regular vascular imaging; patients with severe disease phenotypes (e.g., extensive vascular involvement, cardiac or renal complications) may require indefinite maintenance therapy. 42

Key Pitfalls to Avoid

Do not rely on inflammatory markers alone for disease activity assessment; they are normal in roughly half of active cases. 42
Do not use glucocorticoid monotherapy except for mild disease or diagnostic uncertainty, as combination therapy reduces steroid toxicity. 42
Do not perform elective surgery during active inflammation, given the markedly worse outcomes. 42
Do not discontinue clinical and imaging surveillance in patients who appear to be in remission, because silent vascular progression can occur. 42

PET Imaging Scoring for Large‑Vessel Vasculitis

Disease‑Activity Assessment

Assess the PET Vascular Activity Score (VAS) or Total Vascular Score, which evaluate 9–12 vascular territories on a semiquantitative 0–3 scale; higher scores are associated with greater disease activity and are used to guide the intensity of immunosuppressive therapy【43】.